Breakthrough T1D recently updated the project scope to emphasize a preference for wearable or at-home platforms that demonstrate sensitivity to picomolar C-peptide concentrations. You may now also be eligible for additional funding to support independent third-party validation of promising results. If you are applying for an industry partnership (IDDP), a new dedicated contact has been added to assist with your inquiries.
Funder: Breakthrough T1D
Due Dates: December 4, 2025 (Letter of Intent) | February 12, 2026 (Full Proposal)
Funding Amounts: Up to $900,000 total for up to 3 years; higher budgets/durations considered with strong justification.
Summary: Supports early-stage and preclinical development of innovative, user-friendly technologies for continuous C-peptide monitoring in type 1 diabetes.
Key Information: LOI required before full proposal; open to academic and industry applicants worldwide.